caa a22 4500 606206906 CHVBK 20210128101013.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10353-015-0362-4 doi (NATIONALLICENCE)springer-10.1007/s10353-015-0362-4 Austrian expert panel recommendation for radiofrequency ablation of Barrett's esophagus [Elektronische Daten] [I. Kristo, S.F. Schoppmann, M. Riegler, A. Püspök, K. Emmanuel, G. Spaun, F. Wrba, E. Wenzl, R. Schöfl, F. Schreiber, M. Häfner, C. Madl] Summary: Background: Barrett's esophagus (BE) represents the premalignant manifestation of gastroesophageal reflux disease and includes columnar lined esophagus with intestinal metaplasia, low-grade dysplasia, high-grade dysplasia and cancer. Methods: An Austrian panel of expert meeting was held at the Medical University Vienna, June 2015, to establish and define recommendations for the endoscopic treatment of BE with and without dysplasia and cancer. Recommendations are based on critical analysis of published evidence. Statistics were not applied. Results: Diagnosis of cancer and dysplasia is to be reconfirmed by a second expert pathologist. Advanced cancer (> T1a) requires surgical resection ± adjuvant therapies. Treatment of T1a early cancer, high- and low-grade dysplasia should include endoscopic mucosal resection (EMR) and radiofrequency ablation (RFA). In the presence of increased cancer risk, BE without dysplasia should be treated by RFA within clinical studies only. Elimination of any early cancer, dysplasia and IM defines complete response, that is, post RFA histopathology shows squamous, cardiac or oxyntocardiac mucosa lined esophagus (Chandrasoma classification). Follow-up endoscopies are timed according to the base line histopathology. Down grade from cancer to dysplasia or from dysplasia to non-dysplastic BE defines partial response, respectively. Based on esophageal function testing, reflux is treated by medical or surgical therapy. Conclusion: In Austria, RFA ± EMR is recommended for BE containing early cancer or dysplasia. Non-dysplastic BE with an increased cancer risk should be offered RFA within clinical trials to assess the efficacy for cancer prevention in this group of patients. Springer-Verlag Wien, 2015 Barrett's esophagus nationallicence Dysplasia nationallicence Esophageal cancer nationallicence Radiofrequency ablation nationallicence Kristo I. Department of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut Schoppmann S.F. Department of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut Riegler M. Department of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut Püspök A. Department of Internal Medicine II, Barmherzige Brüder, Eisenstadt, Austria aut Emmanuel K. Department of General and Visceral Surgery, Krankenhaus Barmherzige Schwestern, Linz, Austia aut Spaun G. Department of General and Visceral Surgery, Krankenhaus Barmherzige Schwestern, Linz, Austia aut Wrba F. Clinical Institute for Pathology, Medical University of Vienna, Vienna, Austria aut Wenzl E. Department of Surgery, Landeskrankenhaus, Feldkirch, Austria aut Schöfl R. Department of Internal Medicine IV, Elisabethinen, Linz, Austria aut Schreiber F. Department of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria aut Häfner M. Deparment of Internal Medicine, St. Elisabeth Krankenhaus, Vienna, Austria aut Madl C. Department of Gastroenterology, Hepatology, Endoscopy and Oncology, Rudolfstiftung, Vienna, Austria aut European Surgery Springer Vienna 47/6(2015-12-01), 319-323 1682-8631 47:6<319 2015 47 10353 https://doi.org/10.1007/s10353-015-0362-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10353-015-0362-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kristo I. Department of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Schoppmann S.F. Department of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Riegler M. Department of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Püspök A. Department of Internal Medicine II, Barmherzige Brüder, Eisenstadt, Austria aut NATIONALLICENCE 700 1- Emmanuel K. Department of General and Visceral Surgery, Krankenhaus Barmherzige Schwestern, Linz, Austia aut NATIONALLICENCE 700 1- Spaun G. Department of General and Visceral Surgery, Krankenhaus Barmherzige Schwestern, Linz, Austia aut NATIONALLICENCE 700 1- Wrba F. Clinical Institute for Pathology, Medical University of Vienna, Vienna, Austria aut NATIONALLICENCE 700 1- Wenzl E. Department of Surgery, Landeskrankenhaus, Feldkirch, Austria aut NATIONALLICENCE 700 1- Schöfl R. Department of Internal Medicine IV, Elisabethinen, Linz, Austria aut NATIONALLICENCE 700 1- Schreiber F. Department of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria aut NATIONALLICENCE 700 1- Häfner M. Deparment of Internal Medicine, St. Elisabeth Krankenhaus, Vienna, Austria aut NATIONALLICENCE 700 1- Madl C. Department of Gastroenterology, Hepatology, Endoscopy and Oncology, Rudolfstiftung, Vienna, Austria aut NATIONALLICENCE 773 0- European Surgery Springer Vienna 47/6(2015-12-01), 319-323 1682-8631 47:6<319 2015 47 10353